Pragmatic Welcomes HRH The Princess Royal to Pragmatic Park for the Opening of the UK's First 300mm Semiconductor Wafer Manufacturing Facility
27.3.2024 14:13:00 EET | Business Wire | Press release
Today, Pragmatic Semiconductor was honoured to welcome HRH The Princess Royal to officially open the UK’s first 300mm semiconductor wafer fabrication line (fab) at Pragmatic Park in Durham. The advanced manufacturing facility produces chips based on Pragmatic’s innovative and unique flexible integrated circuit technology. HRH The Princess Royal was hosted by David Moore, CEO, Pragmatic Semiconductor, with a tour of the clean room and facilities, followed by an unveiling of a site plaque to mark the occasion. Attendees included key customers, ecosystem partners, investors and government officials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327583783/en/
The UK’s first 300mm semiconductor fabrication line at Pragmatic Park, Durham, UK (Photo: Business Wire)
Pragmatic’s FlexICs are low-cost, more sustainable alternatives to silicon chips, ultra-thin, with a flexible form factor they enable connect, sense and compute capabilities, fuelling the Internet of Things (IoT) across multiple sectors including consumer, industrial, healthcare and beyond. The company’s mission is to provide item level intelligence to trillions of smart objects over the next decade across a wide range of applications with significant opportunities in smart packaging of fast-moving consumer goods that will significantly improve levels of reuse and recycling, transforming waste management, and enabling a circular economy. Other use cases include wearables, sensors and flexible controllers.
Pragmatic Park has capacity to host up to nine fabrication lines, each capable of producing billions of chips per year. Pragmatic’s pioneering sustainable approach extends to its manufacturing, using fewer process steps and a more concentrated footprint, than standard silicon fabs. The company’s innovative, optimised manufacturing process supports extremely rapid production cycles of less than 48 hours, at very low cost. The manufacturing process also uses significantly less energy and less water than typical silicon manufacturing, and fewer harmful gases. Pragmatic’s modular ‘Fab-in-a-Box’ approach, supports co-location of end-to-end FlexIC manufacturing at customers sites, rationalising extended supply chains and providing additional levels of security and resilience. The manufacturing facility enables the company to meet the growing demand for its unique technology from customers worldwide. Over the next five years Pragmatic anticipates creating over 500 highly skilled jobs in the North-East of England and Cambridge.
Dave Moore, CEO, Pragmatic Semiconductor said: "Today’s official opening marks a key milestone in Pragmatic’s growth trajectory and for the UK on the global semiconductor stage. I am incredibly proud of what the team has achieved and the ambition of our mission to enable item level intelligence in over a trillion sustainable, smart items over the next decade. Such intelligence at scale has the power to accelerate the digital transformation across industries. Sustainability is at the very core of our technology and extends to how FlexICs enable our customers to further drive innovations and pathways through their products and services towards global net zero goals.”
Francisco Melo, President Solutions Group, Avery Dennison said: “The key to any effective collaboration is a shared mindset. Pragmatic’s innovative approach is reflective of our own, as is its commitment to helping solve business challenges. The opening of an advanced manufacturing chip facility is fantastic news for all technology innovators. Congratulations to Pragmatic on such an important and impressive achievement. I look forward to our clients harnessing the potential of Pragmatic's flexible integrated circuits as part of our evolving inlay portfolio."
Simon Little, Banking & Investments Director, UKIB and Pragmatic Board member said: “The Bank invested in Pragmatic to support low carbon domestic manufacturing of semiconductors in the UK. The official opening of Pragmatic Park in Durham marks a pivotal next step in its journey, and we look forward to seeing the long-term impact of our investment, as Pragmatic scales up its operation and creates highly skilled jobs here in the North-East.”
Niranjan Sirdeshpande, Global Head of M&G’s Catalyst strategy and Pragmatic Board member said: “The UK has a very supportive ecosystem for providing early-stage funding, but it becomes challenging for businesses looking for later stage capital. By providing growth equity to enterprising tech disruptors such as Pragmatic, M&G’s £5 billion Catalyst strategy can help them to scale, provide expertise and partner with them all the way to success. Put to work in this way, patient capital can support economic growth and capture value for peoples' pensions and savings as we transition to a more sustainable economy. We are proud to support Pragmatic’s work in Durham with tech advancement in this critical part of the UK's national infrastructure.”
About Pragmatic Semiconductor
Pragmatic is revolutionising semiconductor fabrication with ultra-low-cost, flexible integrated circuit (FlexIC) technology that makes it quick and easy to embed intelligence almost anywhere.
With rapid cycle times that substantially accelerate time to market, its foundry provides high-volume fabrication at a fraction of the cost of silicon, with a significantly lower environmental impact.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327583783/en/
Contact information
Helen Ledger, SVP of Corporate Marketing, Communications and Public Affairs, PR@pragmaticsemi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
